wide
rang
rna
respiratori
virus
identifi
caus
signific
morbid
mortal
among
transplant
recipi
includ
influenza
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
rhinoviru
human
metapneumoviru
hmpv
coronaviru
bocaviru
polyomavirus
tabl
sever
featur
common
among
virus
transplant
popul
season
respiratori
viral
infect
among
transplant
recipi
usual
follow
gener
popul
virus
caus
rang
diseas
mild
congest
rhinorrhea
sever
tracheobronch
bronchiol
pneumonia
one
viru
exclus
associ
one
clinic
syndrom
ie
ill
croup
etc
diagnost
strategi
initi
broad
attempt
screen
recogn
virus
particular
emphasi
one
might
amen
therapi
symptom
commonli
associ
respiratori
viral
infect
includ
fever
nasal
congest
rhinorrhea
wateri
eye
cough
sore
throat
sputum
product
wheez
short
breath
recipi
often
present
mild
atyp
symptom
lung
transplant
recipi
exampl
may
initi
subject
symptom
short
breath
subtl
chang
pulmonari
function
test
without
typic
symptom
fever
may
absent
transplant
recipi
pneumonia
may
sole
present
sign
symptom
fever
respiratori
symptom
prompt
consider
respiratori
viral
infect
potenti
shed
usual
prolong
among
transplant
recipi
prolong
shed
seen
even
use
antivir
therefor
may
contribut
increas
risk
resist
variant
emerg
recipi
higher
risk
infecti
complic
compar
immunocompet
host
older
studi
initi
evid
progress
lower
tract
involv
virus
occur
frequent
may
part
due
ascertain
bias
sicker
patient
like
seen
physician
specimen
sent
viral
assay
respiratori
viral
infect
signific
risk
factor
subsequ
develop
fungal
bacteri
pneumonia
infect
cmv
viremia
may
complic
respiratori
viral
infect
viral
infect
appear
risk
factor
acut
chronic
reject
greatest
risk
lung
transplant
recipi
concurr
reject
graft
dysfunct
document
solid
organ
transplant
recipi
well
although
lower
frequenc
lung
transplant
recipi
iii
pathogenesi
link
respiratori
viral
infect
reject
clearli
pediatr
solid
organ
lung
transplant
recipi
appear
greatest
risk
rna
viral
infect
sever
cours
complic
potenti
nosocomi
pathogen
potenti
spread
staff
visitor
mild
upper
respiratori
prospect
studi
respiratori
viru
infect
solid
organ
transplant
popul
except
lung
transplant
recipi
studi
retrospect
natur
focus
individu
hospit
infect
addit
studi
evalu
patient
close
time
transplant
specimen
like
obtain
diagnosi
like
lead
overestim
sever
underestim
incid
infect
among
transplant
recipi
one
clinic
distinguish
diseas
caus
rna
virus
diagnosi
use
broad
rang
techniqu
consid
particularli
earli
period
transplant
augment
immunosuppress
respiratori
viral
season
diagnosi
achiev
combin
serolog
viru
cultur
antigen
detect
nucleic
acid
test
serolog
gener
clinic
use
gener
patient
presum
respiratori
viral
infect
nasopharyng
swab
wash
aspir
perform
sent
rapid
antigen
test
avail
although
posit
result
test
may
consid
diagnost
neg
result
rule
infect
rapid
antigen
test
may
detect
limit
number
virus
ie
influenza
andor
rsv
therefor
addit
test
may
warrant
neg
rapid
test
rule
infect
trigger
addit
test
polymeras
chain
reaction
pcr
direct
floresc
antibodi
dfa
cultur
depend
avail
local
upper
tract
sampl
fail
document
caus
respiratori
ill
clinic
radiolog
evid
lower
tract
involv
bronchoalveolar
lavag
consid
sent
rang
avail
test
test
wide
rang
pathogen
import
among
lung
transplant
recipi
rapid
antigen
detect
use
sever
differ
techniqu
avail
influenza
rsv
despit
speed
sensit
may
lower
report
licens
studi
particularli
among
immunocompromis
patient
case
rsv
one
studi
document
sensit
one
rapid
test
method
nasal
wash
specimen
among
immunocompromis
patient
sensit
improv
bal
use
although
viral
cultur
previous
consid
prefer
diagnost
test
molecular
test
tend
provid
higher
yield
detect
wider
rang
virus
time
fashion
standard
cultur
typic
detect
hmpv
coronavirus
bocavirus
polyomavirus
hospit
access
molecular
diagnost
respiratori
virus
although
increasingli
avail
refer
laboratori
diagnost
strategi
yield
cultur
depend
site
sampl
greatest
yield
bal
nasal
wash
sever
studi
dfa
test
primari
patient
specimen
document
sensit
approach
pcr
certain
virus
dfa
test
limit
lack
reagent
virus
hmpv
rhinoviru
coronaviru
appear
less
sensit
pcr
detect
dual
infect
like
pcr
though
dfa
test
detect
sever
virus
singl
specimen
wide
rang
assay
detect
respiratori
viru
commerci
avail
mani
center
local
develop
assay
detect
select
virus
avail
assay
abl
screen
wide
rang
pathogen
tandem
mani
test
transplant
popul
nucleic
acid
amplif
assay
appear
sensit
diagnost
tool
avail
allow
simultan
detect
broad
rang
respiratori
pathogen
singl
sampl
therefor
prefer
test
method
immunocompromis
patient
influenza
virus
orthomyxoviru
associ
substanti
morbid
mortal
worldwid
epidem
winter
month
antigen
variabl
give
viru
surviv
advantag
allow
continu
virul
yearli
epidem
studi
examin
preval
influenza
viru
infect
prospect
organ
transplant
recipi
risk
diseas
complic
appear
greatest
pediatr
lung
transplant
patient
variabl
level
sever
transplant
popul
transmiss
occur
inhal
infecti
droplet
contact
fomit
form
influenza
particularli
avian
influenza
may
spread
aerosol
patient
known
suspect
influenza
isol
patient
use
standard
droplet
precaut
two
type
influenza
vaccin
current
avail
number
formul
inject
kill
vaccin
singl
inhal
live
attenu
vaccin
inject
vaccin
studi
transplant
patient
found
safe
associ
increas
risk
reject
advers
outcom
potenti
replic
live
attenu
vaccin
use
contraind
highli
immun
suppress
patient
close
contact
although
respons
vari
base
vaccin
year
specif
influenza
strain
immunosuppress
recipi
type
respons
transplant
recipi
less
robust
healthi
control
recipi
benefit
accordingli
annual
trival
inactiv
influenza
vaccin
strongli
recommend
transplant
recipi
close
contact
caretak
month
age
antivir
chemoprophylaxi
consid
altern
supplement
vaccin
agent
activ
circul
influenza
strain
use
random
studi
oseltamivir
prophylaxi
transplant
recipi
found
protect
efficaci
note
also
receiv
vaccin
two
class
antivir
compound
approv
treatment
influenza
inhibitor
amantadin
rimantadin
tabl
effect
suscept
influenza
strain
neuraminidas
inhibitor
zanamivir
oseltamivir
tabl
activ
suscept
influenza
b
virus
treatment
agent
transplant
recipi
studi
case
report
associ
reduc
risk
lower
respiratori
tract
complic
eg
bronchiol
pneumonia
durat
symptom
mortal
possibl
reduc
risk
progress
bronchiol
obliteran
infect
iii
prospect
studi
conduct
although
dose
rang
studi
oseltamivir
underway
frequent
chang
recommend
manag
influenza
base
current
circul
strain
treatment
decis
align
current
recommend
outlin
center
diseas
control
prevent
http
wwwcdcgovflu
key
caveat
treatment
influenza
transplant
recipi
recogn
first
patient
prolong
viral
replic
even
therapi
approv
day
durat
therapi
may
insuffici
treat
transplant
recipi
likewis
immunocompromis
transplant
recipi
may
benefit
therapi
even
symptom
beyond
h
present
higher
dose
medic
combin
antivir
may
benefit
transplant
recipi
expert
recommend
treat
transplant
recipi
proven
influenza
irrespect
symptom
onset
continu
therapi
viral
replic
document
ceas
cultur
method
use
monitor
patient
shed
iii
final
resist
avail
antivir
complic
routin
manag
influenza
gener
nearli
influenza
virus
resist
inhibitor
resist
affect
amantadin
rimantadin
equal
mani
influenza
virus
develop
resist
oseltamivir
although
current
retain
suscept
zanamivir
also
suscept
inhibitor
limit
data
use
zanamivir
lung
transplant
recipi
patient
underli
lung
diseas
zanamivir
use
rescu
inhal
readili
avail
first
dose
given
monitor
set
recommend
optim
manag
influenza
updat
base
surveil
circul
strain
suscept
current
dose
recommend
health
author
consult
regularli
rsv
paramyxoviru
genu
pneumoviru
caus
season
annual
epidem
worldwid
diseas
seen
tropic
locat
year
age
virtual
children
experienc
primari
infect
although
reinfect
occur
throughout
life
risk
factor
sever
diseas
organ
transplant
includ
infect
children
year
age
underli
lung
diseas
earli
acquisit
rsv
transplant
augment
immunosuppress
associ
increas
sever
diseas
studi
transmiss
occur
inhal
infecti
droplet
contact
fomit
patient
known
suspect
rsv
isol
patient
use
standard
contact
precaut
prophylaxi
monoclon
antibodi
palivizumab
high
titer
shown
effect
specif
group
infant
young
children
howev
studi
conduct
evalu
use
transplant
set
cost
weight
adjust
dose
product
adult
would
extrem
high
despit
expert
would
support
use
immunoprophylaxi
children
less
year
age
receiv
transplant
rsv
season
iii
survey
data
suggest
prophylaxi
commonli
use
among
pediatr
transplant
center
approv
vaccin
treatment
rsv
given
limit
data
treatment
rsv
support
care
recommend
reduct
immun
suppress
consid
particularli
sever
diseas
role
specif
antivir
treatment
controversi
ribavirin
shown
vitro
activ
rsv
aerosol
form
drug
approv
treatment
lower
respiratori
tract
diseas
due
rsv
certain
popul
despit
fda
approv
convinc
data
describ
clinic
efficaci
agent
lack
consensu
util
drug
treatment
rsv
diseas
current
exist
publish
data
treatment
rsv
diseas
solid
organ
transplant
recipi
limit
experi
stem
cell
transplant
popul
suggest
use
aerosol
ribavirin
may
reduc
mortal
associ
sever
rsv
infect
particularli
affect
lower
airway
combin
aerosol
ribavirin
intervent
includ
igiv
palivizumab
appear
even
greater
impact
mortal
mani
expert
therefor
would
recommend
use
combin
aerosol
ribavirin
antibodi
prepar
treatment
sever
rsv
infect
base
upon
publish
experi
pediatr
organ
transplant
recipi
patient
without
risk
factor
sever
diseas
upper
respiratori
infect
unlik
benefit
aerosol
ribavirin
publish
report
success
treatment
rsv
lung
transplant
recipi
oral
iv
ribavirin
without
corticosteroid
studi
need
determin
clinic
efficaci
altern
risk
advers
effect
notabl
hemolyt
anemia
parainfluenza
pneumoviru
four
type
commonli
caus
diseas
human
type
piv
type
tend
circul
sporad
fall
winter
month
temper
area
wherea
type
occur
year
round
type
least
commonli
isol
epidemiolog
still
defin
transmiss
occur
via
person
spread
direct
contact
infecti
secret
fomit
diseas
seriou
particularli
pediatr
transplant
recipi
lung
transplant
recipi
age
although
respiratori
virus
associ
increas
risk
progress
oblit
bronchiol
lung
transplant
recipi
associ
appear
clearest
strongest
piv
lower
tract
diseas
patient
known
suspect
piv
isol
patient
use
standard
contact
precaut
approv
vaccin
recogn
prevent
antivir
agent
although
use
igiv
ribavirin
associ
benefit
manag
piv
infect
stem
cell
transplant
recipi
ribavirin
vitro
activ
use
treat
lung
transplant
recipi
lower
tract
diseas
expert
also
consid
use
igiv
well
hmpv
discov
rel
newli
recogn
pneumoviru
clinic
pattern
similar
rsv
signific
caus
diseas
transplant
recipi
pneumovirus
vaccin
prevent
focus
tight
infect
control
measur
includ
contact
precaut
case
report
anim
data
suggest
ribavirin
igiv
consid
manag
sever
case
hmpv
support
care
remain
mainstay
treatment
human
rhinovirus
hrv
member
picornavirida
famili
common
caus
cold
adult
children
recogn
caus
clinic
signific
diseas
transplant
recipi
fatal
case
describ
fatal
associ
coinfect
prolong
shed
minim
symptom
describ
particularli
lung
transplant
recipi
clinic
import
prolong
shed
fulli
defin
although
could
potenti
pose
threat
nosocomi
transmiss
pleconaril
studi
extens
healthi
adult
rhinovir
upper
respiratori
infect
well
toler
led
faster
resolut
symptom
rapid
improv
symptom
score
clearanc
viru
nasal
mucou
howev
approv
use
fda
due
safeti
concern
current
approv
prevent
therapeut
intervent
use
molecular
diagnost
wider
rang
respiratori
virus
isol
mani
virus
newli
recogn
variant
coronaviru
polyomavirus
wu
ki
virus
bocaviru
wide
studi
transplant
recipi
clinic
impact
fulli
assess
sever
sometim
fatal
case
virus
immunocompromis
patient
recogn
consid
differenti
diagnosi
patient
present
sever
lower
tract
diseas
newer
agent
challeng
diagnos
includ
routin
clinic
avail
diagnost
test
addit
optim
manag
agent
defin
although
respiratori
virus
increasingli
recogn
caus
morbid
mortal
transplant
recipi
still
much
learn
impact
virus
prospect
studi
involv
inpati
outpati
use
molecular
diagnost
need
understand
true
epidemiolog
clinic
spectrum
respiratori
viral
diseas
particular
studi
consequ
infect
even
mild
asymptomat
infect
need
particularli
lung
transplant
recipi
lower
tract
infect
associ
increas
risk
chronic
reject
prospect
studi
use
contemporari
molecular
diagnost
tool
also
need
defin
efficaci
cost
prevent
intervent
particularli
pediatr
popul
final
prospect
therapeut
trial
need
defin
optim
time
durat
treatment
regimen
virus
need
michael
grant
support
sanofi
pasteur
roch
ison
mg
consult
biocryst
adama
roch
lectur
fee
abbott
molecular
viracor
site
pi
viracor
biocryst
roch
